Authors: Schwaab, T Lewis, LD Cole, BF Deo, Y Fanger, MW Wallace, P Guyre, PM Kaufman, PA Heaney, JA Schned, AR Harris, RD Ernstoff, MS

Citation: T. Schwaab et al., Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI Xanti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu, J IMMUNOTH, 24(1), 2001, pp. 79-87

Authors: Schwaab, T Heaney, JA Schned, AR Harris, RD Cole, BF Noelle, RJ Phillips, DM Stempkowski, L Ernstoff, MS

Citation: T. Schwaab et al., A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha 2b therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters, J UROL, 163(4), 2000, pp. 1322-1327

Authors: Ellison, LM Heaney, JA Birkmeyer, JD

Citation: Lm. Ellison et al., The effect of hospital volume on mortality and resource use after radical prostatectomy, J UROL, 163(3), 2000, pp. 867-869

Authors: Curtis, MR Heaney, JA Amdur, RJ Schned, AR Harris, R Ernstoff, MS

Citation: Mr. Curtis et al., Prostatic carcinoma, STRATEGIES IN ADJUVANT THERAPY, 2000, pp. 105-131

Authors: Lerner, LB Andrews, SJ Gonzalez, JL Heaney, JA Currie, JL

Citation: Lb. Lerner et al., Vulvar metastases secondary to transitional cell carcinoma of the bladder - A case report, J REPRO MED, 44(8), 1999, pp. 729-732

Authors: Schwaab, T Schned, AR Heaney, JA Cole, BF Atzpodien, J Wittke, F Ernstoff, MS

Citation: T. Schwaab et al., In vivo description of dendritic cells in human renal cell carcinoma, J UROL, 162(2), 1999, pp. 567-573